News, trends, and stories from the synthetic biology industry
Hi , This week, we bring you the latest update on who owns CRISPR, news of Incripta’s Onyx Platform, Synthetic Biology Clubhouse breaking news, and the latest Biopharma Conference speakers. People without a Clubhouse account will be able to join the session by using our link and skip the
waitlist.
Join us TODAY at 8 am PSTfor What’s Hot in Synthetic Biology with SynBioBeta! Check this week’s exciting expert
speakers:
Mike Kamdar, the CEO of Molecular
Assemblies, who will be talking about the latest technology about to sweep through the enzymatic DNA synthesis industry. The company recently closed an oversubscribed $24 million Series A financing.
Congrats to Andras Forgacs (John Cumbers is a long time investor in Modern Meadow) for their oversubscribed $130 million Series C financing. They are using biofabrication as a way to reimagine how the world approaches materials, sustainability and consumption.
Dylan George, who is joining Concentric by Ginkgo, Ginkgo Bioworks’ public
health and biosecurity effort, as vice president of Business Development.
Who Owns CRISPR in 2021: It’s Even More Complicated Than You Think The question of who owns CRISPR is increasingly complicated. Seen by many as the future of medicine, owning even a small piece of the technology could be extremely valuable. What CRISPR IP scenarios are possible? Is a CRISPR-rights monopoly likely? How could the ongoing patent disputes affect future synthetic biology innovation?
Inscripta introduced the world to its Onyx platform at SynBioBeta 2019. Now, less than two years later, the first commercial shipments of the company's benchtop platform have been shipped out to customers. As synthetic biology tools become smaller and more efficient—sometimes by orders of magnitude—what new kinds of discovery could synthetic biology take on?
The legalization of cannabis has created many opportunities for researchers to study the compounds in the cannabinoid family and discover new uses for them. Demetrix, a synthetic biology company engineering yeast strains to make cannabinoids, is taking research to the next level by signing its first commercial manufacturing contract.
Biopharma Conference
2020 revealed just how underprepared the world was for a global health crisis. But it also confirmed that if the biopharma
community works together, life-saving solutions to our world’s biggest health challenges can be developed in record time. Register now for the event on May 26, and check out the schedule here.
Science News
Register now for the 8th Leaps Talk, which includes a live Q&A session with Yuval Noah Harari, on May 5th at 5pm CET. This discussion is not to be missed. The talk will feature actress, author, and neuroscientist, Mayim Bialik, historian, philosopher, and bestselling author, Yuval Noah Harari, and moderator Niko Woischnik, Founder of Tech Open Air.
DNA Script announced a partnership with Moderna to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA Nucleic Acids On-Demand World-Wide (NOW) Program. DNA Script will receive up to $5 million in grant funding from DARPA.
By cracking open a cellular membrane, Northwestern University synthetic biologists have discovered a new way to increase production yields of protein-based vaccines by five-fold, significantly broadening access to potentially lifesaving medicines.
KSQ Therapeutics is using CRISPR to alter genes across millions of cells. By observing the effect of turning on and off individual genes, KSQ can decipher their role in diseases like cancer. The company uses those insights to develop new treatments.
Orbillion Bio’s plans to make high-end meats in a lab have investors lining up for a seat at the company’s cap table. Mere weeks after launching from Y Combinator’s famous accelerator program, the company has brought in $5 million in financing.
